Battle KE, Lucas TCD, Nguyen M, et al. - Via a spatial and temporal modeling study, researchers exhibited the first global maps of Plasmodium vivax clinical burden from 2000 to 2017. For the Global Burden of Disease 2017 study, outcomes were merged with those for P falciparum (published separately) to form the malaria estimates. A 41.6% reduction, from 24.5 million to 14.3 million cases in 2000 and 2017, respectively was seen in the burden of P vivax malaria. The Americas had a decrease of 56.8% in total cases since 2000, while South-East Asia saw drops of 50.5% and the Western Pacific regions saw drops of 51.3%. Nevertheless, rates of decrease had plateaued in the past five years for many countries, increases have been specifically seen in regions with political and economic instability. Important spatial and temporal patterns in the clinical burden and prevalence of P vivax were reflected via this study. Global monitoring systems were supported, further, it could notify the optimization of diagnosis and treatment where P vivax has the most influence.